Summary: Biolux Technology secured $4.5 million in seed funding to launch a digital platform for OrthoPulse, advance clinical research, and scale operations. The company also appointed Raphael Pascaud as Chairman to guide its next phase of growth.

Key Takeaways:

  • The investment will enable Biolux to enhance OrthoPulse with real-time monitoring and optimized treatment capabilities.
  • Leadership from Raphael Pascaud and partnerships with redalpine and Revere Partners position Biolux for rapid expansion in the orthodontic market.

Biolux Technology announced a $4.5 million investment in its seed fund stage from leading European VC redalpine and Revere Partners, a venture capital fund focused on oral health.

Advancing OrthoPulse with a Digital Platform

Biolux will use the funds to launch a smart digital platform for its flagship product, OrthoPulse, offering real-time monitoring and treatment optimization for both orthodontists and patients.

Alongside these developments, Biolux Technology also announced the appointment of Raphael Pascaud as Chairman of the Board. Mr. Pascaud brings a wealth of leadership experience from his roles on various boards and executive positions in the dental industry, including at companies like DentalMonitoring and Align Technology. With his deep industry expertise, Mr. Pascaud will help in steering Biolux through its next phase of growth and innovation.

READ MORE: Biolux Technology Launches OrthoPulse in the U.S.

“We are thrilled to partner with both redalpine and Revere Partners, and welcome Raphael Pascaud as our Chairman,” said Marcel Pordes, chief executive officer of Biolux Technology. “This investment, along with our new digital platform for OrthoPulse, represents a critical milestone in our journey to revolutionize orthodontics. We are committed to providing patients with faster, more efficient treatment options, and ensuring orthodontists have the tools they need to deliver exceptional care.”

Funding New Innovation

The next-generation OrthoPulse features a patented light-accelerated technology designed for more reliable treatment. Using safe near-infrared light therapy, OrthoPulse accelerates tooth movement. This approach is designed to not only shorten the orthodontic process but also tackles a critical issue in patient care – longer treatments can lead to reduced compliance and more expensive, time-consuming refinements. With this new funding, Biolux Technology will accelerate the development of OrthoPulse, advance clinical research, and develop innovative solutions.

“Biolux is already transforming orthodontics and delivering exceptional patient outcomes with its FDA-cleared, patented, and commercially successful flagship product, OrthoPulse,” said Daniel Dillinger, Principal at redalpine. “We’re delighted to partner with the Biolux team as they enter the next phase of growth, further enhancing the state-of-the-art user experience to support their rapid scaling and expansion in the U.S. market.”

Photo courtesy of Biolux